Inclusion Criteria:

• Participant must be ≥ 18 years of age at the time of  signing informed consent.
• Diagnosis of mature aggressive large B cell non-Hodgkin lymphoma or Follicular  lymphoma Grade 3B.
• Tumor must be cluster of differentiation (CD) 20 positive by immunohistochemistry.
• Have relapsed or refractory disease after ≥ 2 lines of standard therapy and relapsed within 12 months of last therapy.
• Measurable disease as defined by Lugano 2014 classification.
• Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1.

Exclusion Criteria: 

• Diagnosis of Human herpes virus (HHV) 8-positive Diffuse large B Cell lymphoma (DLBCL).
• Prior allogeneic Hematopoietic stem cell transplantation (HSCT).
• Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T- cell infusion.
• Uncontrolled active infections.
• History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis [DVT]).
• History of stroke, unstable angina, myocardial infarction, congestive heart failure (New York Heart Association [NYHA] Class III or IV), severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of  screening.
• History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,  cerebellar disease or neurodegenerative disorder.
• Known history or prior diagnosis of optic neuritis or other immunologic or  inflammatory disease affecting the central nervous system.
• Active central nervous system (CNS) involvement by malignancy.
• Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/23/23. Questions regarding updates should be directed to the study team contact.